The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin D metabolites

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 1, 2005, Pages 16-23

  Ando, Ryoichi ^a   Naito, Shotaro ^a   Inagaki, Yuichro ^a   Hata, Toshihiko ^a   Ishida, Yuji ^b   Chida, Yoshiko ^c   Takayama, Masayuki ^d   Tachibana, Ken ^e   Ohtsuka, Masakazu ^f   Inoue, Atsushi ^f  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b Kyonan Clinic   (Japan)

^c Nakano Bird Clinic   (Japan)

^d Takayama Clinic   (Japan)

^e Tachibana Clinic   (Japan)

^f Shimo Ochiai Clinic   (Japan)

Author keywords

Calcitriol; Dialysate calcium; Hemodialysis; Hyperphosphatemia; Maxacalcitol; Secondary hyperparathyroidism; Sevelamer hydrochloride

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSATE LEVEL; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MALE; NEPHROSCLEROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

CALCITRIOL; CALCIUM; CALCIUM CHANNEL AGONISTS; CASE-CONTROL STUDIES; EPOXY COMPOUNDS; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; TIME FACTORS;

EID: 20144381644     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00216.x     Document Type: Article

References (20)

1. Lopez-Hilker S, Dusso A, Rapp NS, Martin KJ, Slatoplsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990;259:F432-7.
2. Slatopolsky E, Finch J, Denda M. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-40.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
4. Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:1-32.
5. Hercz G, Coburn JW. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int Suppl 1987;22:S215-20.
6. Slatopolsky E, Weerts C, Thielen J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;G78:1097-102.
7. Akiba T, Ando R, Shioyama K. Intermittent high-dose oral 1,25-dihydroxyvitamin D for secondary hyperparathyroidism in hemodialysis patients. J Bone Miner Metab 1991;G9:287-94.
8. Abe J, Takita Y, Nakano T, Miyaura C, Suda T, Nishii Y. A synthetic analogue of vitamin D3,22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989;124:2645-7.
9. Brown AJ, Ritter CR, Finch JL et al. The non calcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;G84:728-32.
10. Akizawa T, Ohashi Y, Akiba T et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004;8:480-91.
11. Muhammedi MA, Piraino B, Rault R, Johnston JR, Puschett JB. Iatrogenic hypercalcemia in hemodialysis patients. Clin Nephrol 1991;36:258-61.
12. Goldberg DI, Dillon MA, Slatopolsky EA et al. Effect of Renagel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphate, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998;13:2303-10.
13. Slatopolsky EA, Burke SK, Dillon MA. Renagel, a nonabsorbed, calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone: The Renagel Study Group. Kidney Int 1999;55:299-307.
14. National Kidney Foundation. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications. Am J Kidney Dis 2003;42:S1-202.
15. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26.
16. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Longterm effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14.
17. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
18. Sadek T, Mazouz H, Bahloul H et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003;18:582-8.
19. Chudek J, Piecha G, Kokot F, Wiecek A. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients. J Nephrol 2003;16:710-5.
20. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002;17:1643-8.